

Available online on 15.06.2026 at <http://ajprd.com>

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

© 2013-25, publisher and licensee AJPRD, This is an Open Access article which permits unrestricted non-commercial use, provided the original work is properly cited

Open  Access

Review Article

Artificial Intelligence Assisted Design and Optimization of Nanosponges for Targeted Drug Delivery

Pranita Waghmare*, Sameer Shafi, Shivilila Swami, Madhuri Damane, Ankita Gadhave

Department of Pharmaceutics Shivlingeshwar College of Pharmacy, Almala.

ABSTRACT

Pharmaceutical technology has been revolutionized by the new nanotechnology, with the emergence of novel nanocarrier systems for targeted drug delivery systems and controlled drug delivery. Nanoporous systems, such as nanosponges, have been shown to be promising candidates for nanoporous carriers due to their high surface area, tunable porosity, biocompatibility and potential to encapsulate hydrophilic and hydrophobic therapeutic agents. In biomedical applications nanosponges are used to increase the solubility, stability, bioavailability and controlled release of drugs to improve their therapeutic efficacy. But the conventional method of preparing nanosponge (NS) is largely based on trial-and-error experimentation, which is time consuming, labor intensive and expensive. In recent years, Artificial Intelligence (AI) has proven to be a gamechanger in the field of pharmaceutical formulation, offering a range of predictive modeling, machine learning, deep learning, molecular simulations, and intelligent optimization techniques that can expedite the formulation development process. With the assistance of AI, NS engineering can be integrated to rationally select the polymer, optimize the crosslinking parameters, predict the interaction between the drug and the polymer, assess the toxicity, model the release rate of the drug, and design the personalized therapeutic treatment. AI driven NS systems can also facilitate targeted delivery, stimuli-responsive release, and precision medicine applications. This review highlights the structure of NS, AI methods, computational tools, engineering methods, therapeutic applications, existing challenges, and future prospects for smart NS systems for precision drug delivery.

Keywords: Artificial intelligence, Nanosponges, Machine learning, pharmaceutical nanotechnology, etc.**ARTICLE INFO:** Received 18 Nov. 2025; Review Complete 21 Feb, 2026; Accepted 27 March. 2026; Available online 15 June. 2026**Cite this article as:**Pranita Waghmare, Department of Pharmaceutics Shivlingeshwar College of Pharmacy, Almala, Asian Journal of Pharmaceutical Research and Development. 2026; 14(3):291-298. DOI: <http://dx.doi.org/10.22270/ajprd.v14i3.1803>

*Address for Correspondence:

Dr. Sameer Shafi, Professor and Head Department of Pharmaceutics Shivlingeshwar College of Pharmacy, Almala.

INTRODUCTION

Nanotechnology has emerged as one of the most promising fields in modern pharmaceutical sciences because of its ability to improve therapeutic efficacy, enhance drug stability, and facilitate targeted drug delivery. Among the various nanocarrier systems, nanosponges have attracted significant attention due to their unique porous architecture, high drug loading capacity, controlled release behavior, and versatility in encapsulating both hydrophilic and hydrophobic therapeutic agents. Nanosponges are nanosized three-dimensional crosslinked polymeric networks capable of entrapping drug molecules within their internal cavities and releasing them in a sustained and sitespecific manner. Because of these advantages, NS based systems have demonstrated considerable potential in oral, topical,

parenteral, pulmonary, ocular, and targeted drug delivery applications.

Conventional development of NS formulations primarily relies on empirical trial-and-error approaches involving extensive laboratory experimentation, optimization studies, and physicochemical characterization. Although these traditional methods have significantly contributed to NS research, they are often timeconsuming, laborintensive, expensive, and associated with limited predictive capability. Various formulation parameters such as polymer concentration, crosslinking density, solvent composition, particle size, and drugpolymer interactions greatly influence NS performance, therapeutic efficacy, and stability. Therefore, there is an increasing demand for advanced computational approaches capable of accelerating

formulation development while improving reproducibility, precision, and efficiency.

Artificial Intelligence (AI) has recently emerged as a revolutionary technology capable of transforming pharmaceutical formulation development and drug delivery research. AI includes advanced computational techniques such as machine learning, deep learning, neural networks, predictive analytics, and datadriven modeling systems that can analyze large and complex datasets with remarkable accuracy. Integration of AI into pharmaceutical nanotechnology enables intelligent formulation optimization, predictive modeling, molecular simulation, automated experimentation, and personalized therapeutic design. In NS engineering, AI-assisted systems can establish nonlinear relationships between formulation variables and performance characteristics, thereby reducing dependence on conventional experimental screening methods.

Machine learning algorithms represent one of the most important components of AI-assisted pharmaceutical research. Algorithms such as artificial neural networks, support vector machines, random forest models, and deep learning architectures are increasingly employed for prediction of NS properties including particle size, entrapment efficiency, drug loading capacity, release kinetics, zeta potential, and stability behavior. These intelligent systems can analyze previously reported experimental datasets and identify optimized formulation conditions with improved accuracy and reduced development time. Consequently, AI-assisted predictive modeling significantly reduces experimental burden and resource utilization during NS formulation development.

Computational molecular modeling and molecular docking approaches have further advanced AI-assisted NS engineering. Computational tools such as AutoDock, Schrödinger, SwissDock, and molecular dynamics simulation platforms can predict interactions between therapeutic molecules and NS polymers at the atomic level. These technologies facilitate rational design of NS systems by evaluating binding affinity, encapsulation mechanisms, structural stability, and release behavior before experimental validation. AI-integrated docking systems also improve computational efficiency and predictive accuracy, thereby enabling rapid virtual screening of drug-polymer combinations for targeted drug delivery applications.

Targeted drug delivery remains one of the major objectives of modern nanomedicine because conventional drug administration often results in poor bioavailability, rapid systemic clearance, non-specific distribution, and severe adverse effects. Nanosponges provide an efficient platform for targeted therapeutics due to their porous structure, tunable surface properties, and capability for functionalization with ligands, antibodies, peptides, and stimuli-responsive moieties. AI-assisted optimization of NS systems can improve targeting efficiency through prediction of optimal particle size, surface charge, ligand selection, and release profiles. Stimuli-responsive AI-engineered nanosponges capable of pH-sensitive, temperature-sensitive, magnetic, enzymatic, and redox-triggered drug release have demonstrated promising applications in cancer therapy, neurotherapeutics, antimicrobial treatment, and precision medicine.

The integration of AI with Quality by Design (QbD) principles has further strengthened pharmaceutical NS development. AI-assisted QbD approaches utilize predictive analytics and machine learning algorithms to identify Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) affecting NS performance. These approaches improve formulation robustness, reproducibility, process scalability, and regulatory compliance while minimizing experimental trials. Furthermore, digital twin technology and computational pharmaceuticals have emerged as innovative AI-driven strategies for virtual simulation of NS behavior under physiological conditions, enabling intelligent process monitoring and real-time optimization.

Despite significant advancements, several challenges remain associated with AI-assisted NS engineering, including limited pharmaceutical datasets, lack of standardized computational protocols, model overfitting, interpretability concerns, and high computational costs. However, rapid advancements in generative AI, robotics-assisted formulation, cloud computing, quantum computing, and explainable AI technologies are expected to revolutionize NS research and pharmaceutical nanotechnology. AI-assisted NS systems may therefore play critical roles in next-generation therapeutics, particularly in oncology, neurological disorders, infectious diseases, regenerative medicine, and personalized healthcare.

Artificial Intelligence In Pharmaceutical Nanotechnology

Artificial intelligence (AI) is a game-changing technology in pharmaceutical sciences and nanotechnology, facilitating intelligent data analysis, predictive modelling, automation, and precision therapeutics. AI is used in pharmaceutical nanotechnology for optimizing formulation parameters, predicting therapeutic activity, assessing toxicity, and creating smart nanocarrier systems. By combining AI with NS formulation engineering, formulation development has been drastically sped up and the number of experiments has been dramatically reduced, and the development cost has reduced, and the time-consuming trial-and-error processes have been shortened. The use of AI-assisted NS systems for targeted therapeutics, personalized medicine, and controlled drug delivery and for translational nanomedicine applications is growing in interest.

Overview of Ai In Drug Delivery

AI-based systems can analyze vast amounts of data to discover patterns and optimize pharmaceutical formulations. AI can speed up drug discovery, enhance formulation reproducibility, and reduce drug development expenses. The integration of AI and nanotechnology allows for the development of intelligent nanocarrier systems that can target specific cells and organs and release drugs at the right time and location.

Machine Learning Algorithms

The use of machine learning algorithms is at the heart of the computational underpinning of AI in nanotechnology for pharmaceuticals, with their ability to predict, classify, optimize, and recognize patterns from experimental data sets leading the way. These algorithms are used in the field of NS engineering to predict the particle size, entrapment efficiency, release kinetics, and therapeutic performance. Artificial Neural Networks (ANNs) provide a good

representation of the nonlinear relationship of formulation variables with NS properties. Random Forest algorithms are used for prediction of loading and stability parameters of drugs and the Support Vector Machines (SVMs) are used for drug formulation classification and toxicity prediction. Advanced approaches to image analysis, feature extraction, and multidimensional data processing are offered by deep learning techniques like convolutional neural networks (CNNs) and recurrent neural networks (RNNs).

Predictive Modeling

Predictive modeling plays a crucial role in the engineering of NS for AI-assisted computational pharmaceuticals. It employs machine learning algorithms and statistical methods to forecast the results of a formulation process from experimental data. Predictive models can be useful in the development of NS to predict particle size, entrapment efficiency, drug loading, drug release kinetics, stability and toxicity profile. These computational methods minimize experimental efforts and speed up formulation optimization. AI algorithms can also help with pre-clinical toxicity assessment and safety evaluation for predictive systems. Moreover, predictive modeling allows the screening of formulation parameters in a fast way, increases the reproducibility of a product and rational formulation design that reduces pharmaceutical product development time and costs.

Molecular Modeling and Docking

AI-guided NS engineering relies on various computational techniques, including molecular modeling and docking, which are crucial for predicting drug-polymer interactions, molecular stability, and the ability to encapsulate the drug. The docking tools, including AutoDock, Schrödinger and SwissDock, simulate therapeutic agents and NS matrices to

enhance the formulation design. These formulations increase solubility, bioavailability and controlled release properties. AI-powered docking platforms also enable virtual screening and targeted drug delivery applications, speeding up the development of cutting-edge NS based nanocarrier systems.

Digital Twins and Computational Pharmaceuticals

Digital twin technology is an emerging innovation in pharmaceutical nanotechnology, enabling the virtual representation of NS systems for in-simulations of the behavior of the formulation, drug release, stability and biological interaction in real time. Digital twins powered by artificial intelligence (AI) can incorporate computational modeling, machine learning, and simulation capabilities to enhance the design and production of NS technology. Improving process control, reproducibility and scalability, and reducing experimental cost and failures. Cloud computing integration could also further enable autonomous formulation development and personalized use of nanomedicine.

AI Assisted Quality by Design

Quality by Design (QbD) is a systematic pharmaceutical development strategy that involves formulation optimization, process understanding and risk management. Using AI-assisted QbD, machine learning, predictive analytics, and computational modeling techniques are used to find Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) for the engineering of NS. These smart systems optimize formulations, enhance reproducibility, control processes and ensure regulatory compliance and decrease experimental trials. AI-integrated QbD also facilitates real-time monitoring, industrial scaling and submission of data to regulatory authorities for the advanced drug delivery systems based on nanosponges.




Figure 1: AI Assisted Design and Optimization of Nanosponges for Targeted Drug delivery




Figure 2: Overview of AI in Drug Delivery

AI ASSISTED ENGINEERING OF NANOSPONGES

The use of AI for nanosponges engineering is a paradigm shift in the pharmaceutical formulation development. The integration of computational approaches allows nanosponge's intelligent design, optimization and prediction.

AI based Polymer Selection

Selection of suitable polymers is critical for NS performance. AI models can predict compatibility between polymers and drug molecules based on molecular descriptors and physicochemical properties. Machine learning algorithms assist in identifying optimal polymer combinations for enhanced drug loading and stability.

Optimization of Crosslinking Parameters

Crosslinking density influences porosity, mechanical strength, and release behavior of nanosponges. AI-assisted optimization can determine ideal crosslinker concentration and reaction conditions. Predictive analytics reduce the need for extensive experimental trials.

Drug Polymer Interaction Prediction

Computational modeling tools enable prediction of drug-polymer interactions and encapsulation efficiency. Molecular dynamics simulations and docking studies provide insights into molecular stability and release mechanisms.

AI for Controlled Release Systems

AI algorithms can optimize release profiles by analyzing formulation variables and environmental conditions. Intelligent NS systems capable of stimuli-responsive release can be developed through AI-driven optimization.

Surface Functionalization and Targeting

Surface modification of nanosponges enhances targeting efficiency and cellular uptake. AI tools can predict ligand-receptor interactions and optimize targeting moieties. Targeted NS systems improve therapeutic efficacy while minimizing off-target effects.

Personalized Nanosponges

Precision medicine aims to provide individualized treatment strategies. AI-assisted NS systems can be tailored according to patient-specific parameters including genetics, disease progression, and pharmacokinetic variability.

Integration with Internet of Medical Things

Smart NS systems integrated with wearable devices and biosensors can facilitate real-time monitoring and personalized therapy. AI-enabled platforms can adjust drug release based on physiological signals.




Figure 3: AI Assisted Engineering of Nanosponges

APPLICATIONS OF AI ASSISTED NANOSPONGES

AI assisted nanosponges exhibit broad applications across various therapeutic areas.

Cancer Therapy

Cancer is still one of the major causes of death in the world. Traditional chemotherapies can cause serious side effects and are not well targeted. NSs fabricated with the help of AI can optimize the size, surface properties, and type of ligand to facilitate more effective drug delivery of anticancer drugs. Site specific release is achieved with stimuli responsive nanosponges. AI based predictive models can finetune the dosing regimens and combinations of drugs. Nanosponges containing doxorubicin, paclitaxel, curcumin and cisplatin have been shown to improve therapeutic effectiveness and decrease toxicity.

Brain Drug Delivery

Any therapeutic agent crossing the blood brain barrier is major headache. Targeted delivery to the central nervous system can be achieved through NS systems, with the help of AI. Surface functionalized nanospheres enhance the permeability and receptor mediated transport. Applications include therapeutics delivery for Alzheimer's, Parkinson's, epilepsy and glioblastoma. The permeability of the blood brain barrier can be predicted by AI algorithms, and targeting strategies optimized.

Antimicrobial Delivery

The threat of antimicrobial resistance is a significant health issue worldwide. Nanosponges can enhance delivery of antibiotics and antimicrobial agents. Optimization with the help of AI leads to better encapsulation efficiency and sustained release behavior. The nanosponge systems can be made responsive to stimuli related to signals that are

associated with infection, releasing antimicrobial agents as a consequence. Machine learning models can be used to optimize combination therapy and synergistic drug delivery. It is a good idea to use a different carrier for each gene and protein.

Gene and Protein Delivery

Biomacromolecules, like proteins, peptides and nucleic acids, are very difficult to deliver because they are prone to degradation by enzymes and are unstable. The nanosponges can create protective environments for sensitive biomolecules. The formulation design is optimized using AI, resulting in more stable and efficient transfection.

Theranostic Applications

In theranostics, therapeutic and diagnostic abilities are combined in a single platform. Nanosponges with imaging agents is an innovative approach that combines diagnostic and therapeutic capabilities through AI. The applications are magnetic resonance imaging, fluorescence imaging and photothermal therapy.

Oral and Topical Delivery

Poorly soluble drugs become more soluble and more bioavailable when they are taken with nanosponges. AI optimized release technology improves bioavailability. The controlled release and enhanced skin penetration by topical NS formulations.

Pulmo-Ocular Delivery

The NS technology is useful in drug delivery systems for the lungs and eyes because it produces sustained release and longer residence time. Aerodynamics and mucoadhesion characteristics can be optimized with the help of AI assisted design.




Figure 4: Applications of AI Assisted Nanosponges

COMPUTATIONAL TOOLS AND SOFTWARE IN AI ASSISTED NANOSPONGE

Computational tools and software play a central role in the development of AI-assisted NS systems by enabling predictive modeling, molecular simulations, optimization of formulation parameters, and intelligent drug delivery design.

The integration of computational pharmaceuticals with artificial intelligence significantly reduces experimental workload, accelerates formulation development, improves reproducibility, and enhances precision medicine approaches. Modern pharmaceutical nanotechnology increasingly depends on machine learning algorithms, molecular docking software, molecular dynamics simulations, quantum mechanical calculations, and statistical optimization platforms for intelligent NS engineering.

Importance of Computational Tools in Nanosponge

Conventional NS development largely relies on trial-and-error experimentation, which is labor-intensive, expensive, and time-consuming. Computational tools provide in silico approaches capable of predicting physicochemical properties, drug-polymer compatibility, release kinetics, toxicity, and biological interactions before laboratory experimentation. AI-assisted computational systems further improve predictive accuracy by learning from large experimental datasets and optimizing formulation variables automatically.

Computational platforms are extensively utilized for:

- Polymer Screening
- Crosslinker Optimization
- Molecular Docking
- Nanoparticle Stability Prediction
- Release Kinetic Modeling
- Toxicity Prediction
- Pharmacokinetic Simulations
- AI-Based Formulation Optimization
- Personalized Medicine Approaches

Machine Learning and Artificial Intelligence Platforms

Machine learning and artificial intelligence platforms are increasingly being utilized in pharmaceutical nanotechnology for predictive analytics, formulation optimization, molecular modeling, and intelligent drug delivery design. In NS engineering, AI-based computational platforms can identify hidden correlations between formulation variables and performance characteristics such as particle size, entrapment efficiency, zeta potential, release kinetics, and therapeutic efficacy. These computational systems reduce dependence on conventional trial-and-error experimentation and facilitate rapid optimization of NS formulations. The integration of machine learning with pharmaceutical nanotechnology has significantly accelerated the development of smart nanocarrier systems for precision medicine applications.

Python

Choices of programming languages in AI, machine learning, and computational pharmacology such as Python are preferred for their flexibility, open-source nature, and the availability of scientific libraries. Python is well-equipped to handle predictive modeling, deep learning, formulation optimization, and data analysis in NS engineering, through tools like TensorFlow, Scikit-learn, PyTorch, NumPy, and

Pandas. Machine learning models based on Python can predict the particle size, entrapment efficiency, release kinetics and stability behavior of nanosponges. Furthermore, toxicity prediction, pharmacokinetic simulation and microscopic image analysis are performed in Python. While Python offers numerous benefits, its use in complex deep learning applications demands programming skills and significant computational power.

MATLAB

The advanced mathematical models and simulation along with user-friendly interface of MATLAB makes it a widely used computational platform in pharmaceutical sciences. In the field of NS engineering, MATLAB is used to model the neural network, to perform optimization studies, conduct pharmacokinetic simulations, perform response surface methodology and kinetic analysis. The software can predict the correlation among formulation variables (like polymer concentrations and crosslinking density) and responses (like particle size, drug loading and release behavior). Optimization of NS methods also includes support for image analysis and genetic algorithms, as well as the machine learning approach to NS optimization in MATLAB. It has excellent mathematical capabilities and powerful visualization capabilities, but disadvantages are that it has costly licensing fees and less flexibility in open source.

Tensor Flow and PyTorch

TensorFlow and PyTorch are the high-level deep learning platforms that are commonly employed in high-tech medicine-related fields such as AI-based drug discovery and nanotechnology. These platforms enable development of neural network models to predict NS characteristics, release kinetics, toxicity, and drug delivery behavior. TensorFlow is the preferred choice for large-scale deep learning tasks, while PyTorch is popular for creating and experimenting with neural networks. They help with image analysis, classification of nanoparticles, prediction of molecules, and generative AI polymer design in NS engineering. Deep learning models are capable of analyzing high-accuracy, complex, high-dimensional data. But these platforms need sophisticated programming skills and powerful computing resources.

CHALLENGES AND LIMITATIONS

While progress has been made, there are still some obstacles that hinder the clinical use of AI-assisted NS systems.

Data Availability and Quality

Large and well-structured sets of data are needed to create machine learning models. There are limited pharmaceutical databases available for standardisation, which limits predictive accuracy. The variability in the experimental conditions makes model development more difficult.

Reproducibility Issues

There are problems with the reproducibility of NS synthesis and characterization. The performance of AI models trained on diverse data sets can be inconsistent.

Regulatory Challenges

The regulation of AI-aided pharmaceutical products is still in its early stages. Regulatory agencies face significant challenges when they try to validate AI algorithms and computational predictions.

Ethical and Security issues

The use of AI systems triggers data privacy, transparency, and algorithmic bias concerns. Personalized medicine applications are especially sensitive to ethical considerations.

Scalability and Manufacturing

It is still challenging to scale up the production of NS without quality loss. AI is a complex technology that will need

significant infrastructure and expertise to integrate into industrial manufacturing.

Toxicity and Biocompatibility

The safety profiles of NS systems need to be studied extensively in the long-term. AI-assisted toxicity prediction models need further validation through clinical studies.

Interdisciplinary Barriers

Implementation of AI-assisted NS systems will require the efforts of pharmaceutical scientists, engineers, data scientists and clinicians. Difficulties with communication between disciplines can impede progress.

FUTURE PERSPECTIVES

Table 1: Future Perspectives

Sr No.	Future Prospect Area	Description
1	Generative AI in Nanosponge Design	Generative AI models can design novel polymers, predict NS architectures, and optimize formulation parameters for enhanced drug delivery performance.
2	Autonomous Laboratories	Integration of robotics and AI-driven automation can enable high-throughput experimentation, rapid screening, and self-optimizing NS formulations.
3	Smart Stimuli-Responsive Nanosponges	Future NS systems may provide self-regulated and site-specific drug release in response to pH, temperature, enzymes, magnetic fields, or redox conditions.
4	Personalized Nanomedicine	AI-assisted NS formulations can be tailored according to patient-specific genetic, proteomic, and pharmacokinetic profiles for precision therapeutics.
5	Neurotherapeutic Drug Delivery	Advanced AI-assisted nanosponges may facilitate efficient blood-brain barrier crossing for treatment of neurological disorders such as Alzheimer's and Parkinson's disease.
6	Infectious Disease Management	Smart NS systems may improve antimicrobial delivery, combat multidrug resistance, and enable controlled release of anti-infective agents.
7	Industrial Scale-Up and Commercialization	AI-assisted optimization can improve reproducibility, scalability, and cost-effective manufacturing of NS formulations for commercial applications.
8	Regenerative Medicine	AI-engineered nanosponges may support tissue engineering, stem cell delivery, wound healing, and regenerative therapeutic applications.

CONCLUSION

The development of nanosponges using AI technology is a major breakthrough in the field of nanotechnology in the medical field and in the area of precision medicine. The incorporation of AI into NS systems has not only optimized formulations but also facilitated predictive modelling, controlled drug delivery and targeted therapeutics, reducing the reliance on traditional trial-and-error methods. Machine learning algorithms, molecular modeling, predictive analytics, and computational pharmaceuticals come into play in

process of intelligent design of NS formulations, which results in the increased efficiency of the encapsulation, controlled release behavior, improved stability and optimized therapeutic performance of the formulations. Some of the most promising applications of AI-assisted NS systems have been in the fields of cancer therapy, brain drug delivery, antimicrobial therapy, gene and protein delivery, theranostics, oral delivery, pulmonary delivery, and personalized medicine.

Regardless of these advances, there are a number of challenges that still need to be overcome, including availability of good quality data, problems with reproducibility, regulatory uncertainty, scalability concerns and long-term toxicity evaluation. To achieve clinical translation of AI assisted NS systems, the experimental protocols need to be standardized, extensive validation studies need to be developed, interdisciplinary collaboration is required, and regulatory frameworks for AI integrated pharmaceutical products need to be established. The potential impact of new technologies like generative AI, self-serving labs, robotic formulation, digital twins, cloud computing, and explainable AI on intelligent NSEngineering will be further explored.

In conclusion, the fusion of AI and NS based nanocarrier technology presents a tremendous opportunity for the creation of the next generation of smart therapeutics for achieving precise, personalized, and efficient drug delivery in modern healthcare.

REFERENCES

1. Trotta F, Zanetti M, Cavalli R. Cyclodextrin-based nanosponges as drug carriers. *Beilstein J Org Chem*. 2012; 8:2091–9.
2. Swaminathan S, Vavia PR, Trotta F, Cavalli R. Nanosponges encapsulating camptothecin: formulation, characterization and cytotoxicity. *Eur J Pharm Biopharm*. 2007;68(3):579–87.
3. Ansari KA, Vavia PR, Trotta F, Cavalli R. Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterization, stability, cytotoxicity and permeation study. *AAPS PharmSciTech*. 2011;12(1):279–86.
4. Cavalli R, Trotta F, Tumiatti W. Cyclodextrin-based nanosponges for drug delivery. *J Incl Phenom Macrocycl Chem*. 2006;56(1–2):209–13.
5. Krabicová I, Appleton SL, Tannous M, et al. History of cyclodextrin nanosponges. *Polymers*. 2020;12(5):1122.
6. Subramaniyan V, et al. Artificial intelligence in pharmaceutical drug delivery and formulation development. *Int J Pharm*. 2022; 620:121715.
7. Paul D, Sanap G, Shenoy S, et al. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;26(1):80–93.
8. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. *Drug Discov Today*. 2019;24(3):773–80.
9. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. *Nat Rev Drug Discov*. 2019;18(6):463–77.
10. Lo Y-C, Rensi SE, Torng W, Altman RB. Machine learning in chemoinformatics and drug discovery. *Drug Discov Today*. 2018;23(8):1538–46.
11. Ekins S, Puhl AC, Zorn KM, et al. Exploiting machine learning for end-to-end drug discovery and development. *Nat Mater*. 2019;18(5):435–41.
12. Schneider G. Automating drug discovery. *Nat Rev Drug Discov*. 2018;17(2):97–113.
13. Zhavoronkov A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat Biotechnol*. 2019;37(9):1038–40.
14. Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583–9.
15. Gromiha MM, Nagarajan R, Selvaraj S. Application of computational techniques in nanomedicine and drug delivery. *Curr Med Chem*. 2019;26(18):3248–65.
16. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Curr Top Med Chem*. 2014;14(16):1923–38.
17. Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J Comput Chem*. 2009;30(16):2785–91.
18. Abraham MJ, Murtola T, Schulz R, et al. GROMACS: high performance molecular simulations through multi-level parallelism. *SoftwareX*. 2015;1–2:19–25.
19. Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. *J Comput Chem*. 2005;26(16):1781–802.
20. Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. *Pharmacol Rev*. 2014;66(1):334–95.
21. Yu H, Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technologies. *Drug Discov Today*. 2003;8(18):852–61.
22. Qiu T, et al. Explainable artificial intelligence for healthcare and medicine. *Brief Bioinform*. 2022;23(4): bbac120.
23. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nat Med*. 2019;25(1):44–56.
24. Ribeiro MT, Singh S, Guestrin C. “Why should I trust you?” Explaining the predictions of any classifier. *Proc ACM SIGKDD Int Conf Knowl Discov Data Min*. 2016:1135–44.
25. ICH Harmonised Guideline. Pharmaceutical development Q8(R2). International Council for Harmonisation; 2009.
26. Waghmare P, Shafi S, Swami S, Gadhawe A, Damane M, Syed SM. Sponging innovations: A new era of porous nanocarriers in drug delivery and biomedical applications. *Curr Pharm Anal*. 2026;22:181-195. doi:10.1016/j.cpan.2025.12.011.
27. Shafi S, Waghmare P, Swami S, Gadhawe A, Damane M. Nanosponges in modern pharmaceuticals: a comprehensive review on structure, functionality, and future directions. *Asian J Pharm Res Dev*. 2025;13(6):130-137. doi:10.22270/ajprd.v13i6.1663.